Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (2 active)

Company-led only

3 records in Main database · 3 strong · 3 status checked

Compare	Program	Company	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications
Add	SENS-401 (Arazasetron) by Sensorion	Sensorion	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	company · Priority 1	94%	AdultSudden / SSNHL+2	Hearing LossSensorineural Hearing Loss+2
Add	SENS-501 by Sensorion	Sensorion	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 1	94%	PediatricCongenital+5	Hearing LossSensorineural Hearing Loss+3
Add	GJB2-GT by Sensorion	Sensorion	Therapeutic	-	Gene Therapy	Preclinical	Active	Details checkedStrong evidence	company · Priority 2	88%	CongenitalGenetic+1	Hearing LossSensorineural Hearing Loss+1